FIELD: medicine; pharmaceuticals.
SUBSTANCE: described are methods of treating and preventing conditions of nasal mucosa or paranasal sinuses. Methods involve administering a pharmaceutical composition comprising a nicotinic acetylcholine receptor agonist (nAChR), for example, (S)-(1-methyl-2-pyrrolidinyl)-pyridine or a pharmaceutically acceptable salt thereof, an analogue, a precursor or a derivative thereof.
EFFECT: methods can be used for treating a wide range of conditions of the nasal mucous membrane or paranasal sinuses, for example, nasal congestion and epistaxis.
18 cl, 2 ex
Authors
Dates
2020-03-30—Published
2017-04-12—Filed